Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Work In Process (2023 - 2024)

Seres Therapeutics' Work In Process history spans 2 years, with the latest figure at $48.1 million for Q2 2024.

  • For Q2 2024, Work In Process rose 911.85% year-over-year to $48.1 million; the TTM value through Jun 2024 reached $48.1 million, up 911.85%, while the annual FY2023 figure was $25.2 million, N/A changed from the prior year.
  • Work In Process for Q2 2024 was $48.1 million at Seres Therapeutics, up from $37.3 million in the prior quarter.
  • Across five years, Work In Process topped out at $48.1 million in Q2 2024 and bottomed at $4.8 million in Q2 2023.